Development of animal models to explore possible relationships between mycoplasmas and chronic progressive respiratory disease of man could take two general courses. One approach could be study of naturally-occurring chronic respiratory diseases associated with mycoplasmas in animals and birds in order to gain insight into the nature of the host-parasite relationship that could be applied subsequently to investigation of human disease. A second approach could involve attempts to produce progressive disease in appropriate experimental hosts using mycoplasmas isolated from patients.
Development of animal models to explore possible relationships between mycoplasmas and chronic progressive respiratory disease of man could take two general courses. One approach could be study of naturally-occurring chronic respiratory diseases associated with mycoplasmas in animals and birds in order to gain insight into the nature of the host-parasite relationship that could be applied subsequently to investigation of human disease. A second approach could involve attempts to produce progressive disease in appropriate experimental hosts using mycoplasmas isolated from patients.
There are a number of chronic respiratory mycoplasmoses of animals and birds: examples include infections with M. pulmonis in rats, M. hyorhinis in swine, and M. gallisepticum in turkeys. Discussion of the epidemiology and pathogenesis of these lesions will be provided by Drs. Fabricant and Thomas. At present no animal mycoplasmoses are known that have pathophysiologic features resembling chronic obstructive respiratory disease of man.
Among the eight distinct mycoplasma species indigenous to man, only Mycoplasma pneumtoniae (Eaton's atypical pneumonia agent) has proven pathogenicity. Two other species are potentially pathogenic, although definitive proof is currently lacking. The first is M. hominis which has been associated with respiratory disease,"'2 has caused septicemia after obstetrical or gynecologic procedures,' and has produced exudative pharyngitis in volunteers.' The second is the T-strain group which is distinct from other mycoplasmas in biologic properties' and contains a multiplicity of serotypes ; these organisms have been associated with nongonococcal urethritis, but it is not clear whether they serve as primary or secondary invaders in this instance.' The remaining species (M. pharyngis, M. salivarium, M. orale types 2 and 3, and M. fermentans) have no known pathogenic significance, and apparently comprise part of the normal microbial flora of the respiratory and genito-urinary tracts. Isolation of these types from a variety of pathologic specimens, such as leukemic bone marrow, suggests that they Mycoplasma disease model C can be opportunistic invaders in debilitated patients. Thus, there is no evidence currently relating mycoplasmas to chronic diseases of man. This paper will be concerned with the only proven human counterpart of the veterinary mycoplasmoses, M. pneumoniae pneumonia. For purposes of this conference, studies involving the Syrian hamster as an experimental model for M. pneumoniae disease will be described to indicate applications of the model system in defining the microbiology, pathology, and immunology of experimental disease. In addition, certain technical nuances will be demonstrated which could apply to the development of other animal models for studies on human mycoplasma infections. The methods used in the work to be summarized have been described in detail elsewhere.8-1°M
ICROBIOLOGIC INVESTIGATIONS An understanding of the temporal aspects of experimental infections is an essential prerequisite for development of a model system. Intranasal inoculation of hamsters with M. pneumoniae broth culture results in colonization throughout the respiratory tract. In the experiment depicted in Figure 1 , over 100 animals were anesthetized with intraperitoneal secobarbital sodium, and each received 103 colony-forming units (CFU) of M. pneumoniae contained in 0.1 ml. of broth culture medium. At intervals, 5-6 animals were sacrificed and serial dilutions of ground lung were cultured for the mycoplasma. This revealed that all animals were infected by 10-14 days after inoculation; multiplication of organisms had proceeded at this point to a level of 106 CFU/gm. of lung tissue. Half of the animals yielded the mycoplasma from their lungs four weeks after inoculation, and complete clearing of infection required 12 weeks. Other studies suggest that colonization may persist somewhat longer in the upper respiratory passages.!
PATHOLOGIC INVESTIGATIONS
Correlation of infection and pulmonary pathologic changes requires close sequential study of both phenomena. No gross changes are apparent at autopsy of infected hamsters, but evidence of pneumonia may be seen microscopically. The appearance of pulmonary abnormalities follows growth of the mycoplasma in the lung by 3-4 days, as shown in Figure 1 , and demonstrates a similar chronology to that described for infection above. The basic lesion is a peribronchial cellular infiltrate, as shown in Figure 2 . Usually these lesions are not marked; uninvolved bronchi and normal pulmonary parenchyma may be seen in the same section. At times an endobronchial exudate may be found, varying in degree from a slight reaction (Fig. 2 ) to a more severe bronchial obstruction, as shown in Figure 3 . The peribronchial infiltration is composed predominantly of small round cells and oc- Fernald.?°c asional plasma cells (Fig. 4) , while the intraluminal exudate consists chiefly of polymorphonuclear leukocytes. No frank tissue destruction is evident in such material. The nature of the histopathology suggests that the changes may be due in large part to mobilization of host defense mechanisms. Further insight could be gained from localization of the organisms in relation to the pathologic reactions, but nothing suggesting mycoplasmal forms can be found in tissue stained with hematoxylin and eosin after formalin fixation (Figures 2-4) . Thus the problem arises of finding appropriate techniques for the task.
Many years ago Eaton found that the organism would replicate in the chick embryo, and Liu visualized the site by using immunofluorescent methods.ul As shown in Figure 5 , which is a section of infected chick embryo bronchus, specific immunofluorescence was localized at the bronchial epithelial border. At this time it was thought that Eaton's agent was a virus related to the Bedsoniae which was multiplying in the cytoplasm of epithelial cells. Marmion and Goodburn"2 applied an intensified Giemsa stain to similar sections fixed in acetone, with the result depicted in Figure 6 . The area revealing specific antigen by immunofluorescence was seen to contain numerous pink-staining minute cocci located in the bronchial mucus layer. This breakthrough led to subsequent proof that Eaton's organism was a mycoplasma.
Application of immunofluorescent methods to study of infected hamster lungs revealed.clumps of specifically-stained material on the bronchial epithelial surface which increased in amount with time, paralleling organ-ism multiplication.8 Companion frozen sections stained by Marmion's method revealed no mycoplasmal forms of the type seen in the chick emp)ryo ( Figure 7) . Resolution of this problem required evaluation of a variety of fixatives and stains, using serial lung sections. Figure 8 , depicting a section paired with that in Figure 7 , reveals extracellular coccal forms corresponding to immunofluorescent areas after fixation in Van de Grift's solution and application of a modified Brown and Brenn staining method.8 With greater magnification (Fig. 9) it can be seen that the coccal forms occur in clumps in the bronchial mucus layer, providing a pattern not unlike that of Bordetella pertussis disease. It is conceivable that the host response in M. pneumoniae disease is mediated, as in pertussis, by extracellular products of the organisms, since the major pathologic changes are at sites distant from the location of the mycoplasmas. The nuances of histologic technique discussed above indicate the importance of methodology in work with mycoplasma models. Two other considerations that bear on successful production of experimental M. pneumoniae disease are the history of the inoculating organism and the choice of anesthetic agent. As indicated in Table 1 , repeated passage of M. pneumoniae in artificial media can reduce organism virulence for the hamster; infection is established after inoculation, but pneumonia does not occur. 8 Similarly Couch, et al.,' have indicated that serial subcultivation of the organisms reduces pathogenicity for volunteers, with the implication that attenuated organisms could be used as vaccines via the respiratory route. These data also suggest that alterations in mycoplasmas resulting from manipulations in the laboratory could impede successful development of other animal model systems. Table 2 summarizes the effect of two anesthetic agents on the response of hamsters to M. pneumoniae inoculation. Animals in Group A received intraperitoneal secobarbital, while those in Group B were given anestheticgrade ether by inhalation. Two weeks after inoculation all animals in Group A were infected with the mycoplasma, yielding a geometric mean count of Figure 10 . On exposure of broth culture to 20 per cent ether, the extrapolated half-life of the organisms was found to be less than 30 seconds. This probably reflects solubility of the sterol and phospholipid membrane components of the mycoplasma in an organic solvent.
IMMUNOLOGIC INVESTIGATIONS
One additional application of the hamster model in studying M. pneumoniae disease is the development of immune responses and how these relate to the pathogenesis of disease. Figure 1 depicts the results of tests for complement-fixing and growth-inhibiting antibodies in hamsters inoculated with virulent M. pneumoniae. The growth inhibition technique as performed in this laboratory involves titration of organisms in 10 per cent antiserum, so that the result is expressed as the capacity of serum to inhibit growth in colony-forming units. This technique has twice the sensitivity of the obverse method, which is titration of serum in the presence of a constant inoculum of organisms.'
Six months were required in the experiment depicted to follow initiation and resolution of infection and pneumonitis, and to detect development and decline of the immune responses measured. Both responses were first detected when pneumonic changes reached their peak, between 2 and 3 weeks post-inoculation. The complement-fixing activity attained its highest level around six weeks, at which point 20 per cent of the animals still had pneumonia. Growth inhibiting ability of serum peaked at about 10 weeks, and provides a better correlation with the disappearance of both organisms and As has been demonstrated earlier, M. pneumoniae infection is superficial in nature, and it is likely that local cellular or secretory immunity plays a major role in resistance to disease.
CONCLUSION
This discussion of an animal model for M. pneumoniae disease has several implications and applications concerning possible relationships between mycoplasmas and chronic obstructive pulmonary disease in man. At present only M. pneumoniae is recognized among the several species indigenous to man as having definite respiratory pathogenicity. While the clinical manifestations of M. pneumoniae disease are acute, and there are as yet no known chronic sequelae, the microbial, epidemiologic, and immunologic aspects follow a more subacute pattern. As with commensal bacteria, commensal mycoplasma species may be recovered from sputa of patients with chronic bronchitis.1" The pathogenic significance of these organisms has not been assessed; a logical first step could be studies of the type that have been described using animal models. While data from such experiments are not directly transferable to man, they may provide insight into basic and essentially unexplored pathogenetic mechanisms which can direct appropriate design and interpretation of studies in the human host.
